Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Eli Lilly and Co    LLY

Delayed Quote. Delayed  - 08/26 10:00:26 pm
78.24 USD   +0.29%
08/24 ELI LILLY AND : Lilly to Participate in Morgan Stanley Global Health..
08/22DJEli Lilly, AstraZeneca Progress With Alzheimer's Drug
08/22DJELI LILLY AND : AstraZeneca Get Fast-Track Designation for Alzheimer..
News SummaryMost relevantAll newsSector news 

Eli Lilly & Co. : Lilly quarterly sales, profit beats forecasts

share with twitter share with LinkedIn share with facebook
share via e-mail
04/25/2012 | 02:01pm CEST

Eli Lilly & Co's quarterly profit fell on plunging sales of its Zyprexa schizophrenia drug, but results handily topped Wall Street forecasts, helped by strong sales of anti-depressant Cymbalta and demand for the company's animal health products.

The earnings beat, relative to investor expectations, was also due to cost controls, surging demand in China for its products and because Zyprexa's decline was not as steep as had been feared, said company spokesman Mark Taylor.

The Indianapolis drugmaker said on Wednesday it earned $1.01 billion, or 91 cents per share in the first quarter. That compared with $1.06 billion, or 95 cents per share, in the year-earlier period, when the company took a number of restructuring and research-related charges.

Excluding special items, Lilly earned 92 cents per share. Analysts, on average, had expected 78 cents per share, according to Thomson Reuters I/B/E/S.

The company's shares rose 2.2 percent in premarket trading.

"Lilly just reported what looks like a solid first quarter," ISI Group analyst Mark Schoenebaum said in a research note.

But Schoenebaum predicted its shares would not react in a major way since investors are more focused on the company's progress in developing solanezumab, its experimental Alzheimer's disease treatment, than on quarterly earnings.

Data from the drug's late-stage trial is expected later this year. Although the drug is considered to be a long shot, investors say it would have huge sales potential if shown to slow progress of the memory-robbing disease, and speed Lilly's return to profit growth.

Global company revenue fell 4 percent to $5.6 billion, little affected by foreign exchange rates, above Wall Street expectations of $5.36 billion.

Sales of Zyprexa, which lost U.S. patent protection in October, tumbled 56 percent to $563 million, while Cymbalta sales jumped 23 percent to $1.11 billion.

Although Cymbalta's growth helped offset declines for Zyprexa in the quarter, the depression drug's own U.S. patent will lapse in mid-2013. Its sales will then shrink dramatically, worsening Lilly's long-feared patent cliff.

Global sales of Alimta, the company's lung cancer drug, rose 5 percent to $607 million. Its Humalog insulin rose 12 percent to $590 million, while its Humulin insulin brand grew 6 percent to $308 million.

The company slightly raised its 2012 profit forecast to between $3.15 and $3.30 per share, excluding special items. In January, Lilly forecast $3.10 to $3.20 per share, far below analyst estimates, sending the drugmaker's stock down sharply.

(Reporting By Ransdell Pierson; Editing by Gerald E. McCormick and Maureen Bavdek)

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ELI LILLY AND CO
08/26 ELI LILLY AND : Assigned Patent
08/25 ELI LILLY AND : Researchers at Eli Lilly Detail Findings in Gastroenterology (As..
08/25 ELI LILLY AND : Study Data from Eli Lilly Update Knowledge of Alzheimer Disease ..
08/25 ELI LILLY AND : An Application for the Trademark "JILITY" Has Been Filed by Eli ..
08/24 ELI LILLY AND : Lilly to Participate in Morgan Stanley Global Healthcare Confere..
08/22DJEli Lilly, AstraZeneca Progress With Alzheimer's Drug
08/22DJELI LILLY AND : AstraZeneca Get Fast-Track Designation for Alzheimer's Drug--Upd..
08/22DJELI LILLY AND : AstraZeneca Get Fast Track Designation for Alzheimer's Drug
08/22 ASTRAZENECA : Eli Lilly Get Fast Track Designation For AZD3239
08/22 ELI LILLY AND : Lilly and AstraZeneca Receive FDA Fast Track Designation for AZD..
More news
Sector news : Pharmaceuticals - NEC
12:53a Stada shareholder AOC pushes through board reshuffle
12:43a ABBOTT LABORATORIES : Whiplashed investors stay skittish about St. Jude
08/26DJST JUDE MEDICAL : . Jude Denies Claims in Muddy Waters Report
08/26DJALERE : Sues Abbott to Force Merger -- 2nd Update
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
08/24 PATENT DISPUTE ELI LILLY AND ACRUX : Update And Opportunity?
08/23 Patent Dispute Off The Rails For Eli Lilly And Acrux
08/22 Lilly and AstraZeneca's AZD3293 Fast Track'd for early Alzheimer's
08/22 Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q2 2016 Update
08/18 The 'Safest' Healthcare Top Dogs Of August?
Financials ($)
Sales 2016 21 147 M
EBIT 2016 4 751 M
Net income 2016 3 314 M
Debt 2016 2 807 M
Yield 2016 2,63%
P/E ratio 2016 27,01
P/E ratio 2017 21,23
EV / Sales 2016 4,22x
EV / Sales 2017 4,03x
Capitalization 86 365 M
More Financials
Duration : Period :
Eli Lilly and Co Technical Analysis Chart | LLY | US5324571083 | 4-Traders
Full-screen chart
Technical analysis trends ELI LILLY AND CO
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 96,7 $
Spread / Average Target 24%
Consensus details
EPS Revisions
More Estimates Revisions
John C. Lechleiter Chairman, President & Chief Executive Officer
Derica W. Rice Chief Financial Officer & EVP-Global Services
Thomas F. Bumol Senior VP-Biotechnology & Autoimmunity Research
Timothy J. Garnett Chief Medical Officer
Jan M. Lundberg Executive Vice President-Science & Technology
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ELI LILLY AND CO-7.14%86 365
JOHNSON & JOHNSON15.89%325 679
ROCHE HOLDING LTD.-11.47%214 671
PFIZER INC.7.87%211 206
NOVARTIS AG-9.62%210 234
More Results